KR102597910B1 - 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물 - Google Patents

숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102597910B1
KR102597910B1 KR1020177031097A KR20177031097A KR102597910B1 KR 102597910 B1 KR102597910 B1 KR 102597910B1 KR 1020177031097 A KR1020177031097 A KR 1020177031097A KR 20177031097 A KR20177031097 A KR 20177031097A KR 102597910 B1 KR102597910 B1 KR 102597910B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
alcohol
naproxen
delete delete
fexofenadine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177031097A
Other languages
English (en)
Korean (ko)
Other versions
KR20170131647A (ko
Inventor
재클린 엠. 이베르센
제임스 엠. 이베르센
Original Assignee
재클린 엠. 이베르센
제임스 엠. 이베르센
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재클린 엠. 이베르센, 제임스 엠. 이베르센 filed Critical 재클린 엠. 이베르센
Publication of KR20170131647A publication Critical patent/KR20170131647A/ko
Application granted granted Critical
Publication of KR102597910B1 publication Critical patent/KR102597910B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020177031097A 2015-03-26 2016-03-18 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물 Active KR102597910B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562138665P 2015-03-26 2015-03-26
US62/138,665 2015-03-26
PCT/US2016/023200 WO2016154028A1 (en) 2015-03-26 2016-03-18 Methods and compositions to inhibit symptoms associated with veisalgia

Publications (2)

Publication Number Publication Date
KR20170131647A KR20170131647A (ko) 2017-11-29
KR102597910B1 true KR102597910B1 (ko) 2023-11-02

Family

ID=56976188

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177031097A Active KR102597910B1 (ko) 2015-03-26 2016-03-18 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물

Country Status (15)

Country Link
US (3) US10420756B2 (enExample)
EP (2) EP3273952B1 (enExample)
JP (1) JP6851365B2 (enExample)
KR (1) KR102597910B1 (enExample)
CN (2) CN115887456A (enExample)
AU (1) AU2016235484B2 (enExample)
BR (1) BR112017020307B1 (enExample)
CA (1) CA2980162C (enExample)
ES (1) ES2926494T3 (enExample)
IL (1) IL254641B2 (enExample)
MX (2) MX390011B (enExample)
NZ (1) NZ735777A (enExample)
PL (1) PL3273952T3 (enExample)
WO (1) WO2016154028A1 (enExample)
ZA (1) ZA201706794B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102597910B1 (ko) * 2015-03-26 2023-11-02 재클린 엠. 이베르센 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
WO2019046201A1 (en) * 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION
US11129803B2 (en) 2017-09-18 2021-09-28 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit tolerance to opioids
WO2019055939A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING SYMPTOMS ASSOCIATED WITH OPIOID WEANING
US10675261B2 (en) 2017-09-18 2020-06-09 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit dependence on opioids
WO2019178516A1 (en) * 2018-03-16 2019-09-19 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040025331A1 (en) 2002-05-16 2004-02-12 Schmitt Klaus Gisbert Joining system head, joining system, and method of feeding and joining elements
US20050203105A1 (en) 2002-08-15 2005-09-15 Tan Oon T. Composition and method for controlling alcohol-induced facial flushing in susceptible humans
US20080021083A1 (en) 2004-03-03 2008-01-24 Daley Thomas E 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
US20110184039A1 (en) 2008-06-20 2011-07-28 Brett Antony Mooney Pharmaceutical formulation

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075426A (en) 1976-03-12 1978-02-21 Harvey Mitchell Gould Parallel silent communicator
US4496548A (en) * 1983-02-04 1985-01-29 Moldowan Mervin J Composition and method for reducing hangover
US5053396A (en) * 1985-08-27 1991-10-01 Blass David H Therapeutic composition
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
WO1992005783A1 (en) * 1990-09-28 1992-04-16 Merck & Co., Inc. Ibuprofen-antihistamine combinations
FI950467A7 (fi) * 1992-08-03 1995-03-31 Sepracor Inc Terfenadiinin metaboliitit ja niiden optisesti puhtaat isomeerit aller gisten sairauksien hoitamiseksi
EP0766960B1 (en) 1995-04-21 2003-09-17 Sekisui Kagaku Kogyo Kabushiki Kaisha External preparations for treating dermatoses
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
DE19708209C2 (de) 1997-02-28 2000-03-02 Hans Juergen Pauling Wiederaufladbare Batterieanordnung und deren Verwendung
US20050281751A1 (en) 1997-07-21 2005-12-22 Bruce Levin Directed intranasal administration of pharmaceutical agents
BR9812660A (pt) * 1997-09-19 2000-08-22 Procter & Gamble Composições e métodos para tratar distúrbios respiratórios
US20030181495A1 (en) 1998-06-23 2003-09-25 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6697361B2 (en) 1998-09-15 2004-02-24 Nortel Networks Limited Method and apparatus for stream aggregation in a multiprotocol label switching network environment
US6274627B1 (en) 1999-10-12 2001-08-14 Medinox, Inc. Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
WO2003009834A1 (en) 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
US20020045184A1 (en) * 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
US7189757B2 (en) 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
WO2003032912A2 (en) 2001-10-16 2003-04-24 Hypnion, Inc. Treatment of cns disorders using cns target modulators
GB0128674D0 (en) 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
EP1471913A2 (en) 2002-01-18 2004-11-03 Hypnion Inc. Treatment of sleep disorders using sleep target modulators
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
CL2003002653A1 (es) * 2002-12-18 2005-04-22 Wyeth Corp Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
GB0312425D0 (en) 2003-05-30 2003-07-09 Boots Co Plc Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith
GB0312419D0 (en) 2003-05-30 2003-07-02 Boots Healthcare Int Ltd Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess
US20070292498A1 (en) 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
GB2435410B (en) * 2004-04-21 2007-12-05 Silent Gliss Internat Ltd Improvements in or relating to curtain heading systems
EP1782831B1 (en) 2004-08-18 2011-10-19 Medrx Co., Ltd. External preparation
DK1804804T3 (da) 2004-09-21 2012-02-20 Hypnion Inc 3-[4-(dibenzo[b,f][1,4]oxazepin-11-yl)-piperazin-1-yl]-2,2-dimethylpropansyre til anvendelse ved behandlingen af søvnforstyrrelser
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
WO2006049734A2 (en) 2004-10-29 2006-05-11 Hypnion, Inc. Quetiapine analogs and methods of use thereof
CA2588943C (en) 2004-12-15 2013-02-26 Saitama Daiichi Pharmaceutical Co., Ltd. Medical tape preparation
AU2005316295B2 (en) 2004-12-17 2012-03-22 Alan B. Cash Method for extending lifespan and delaying the onset of age-related disease
JPWO2006087968A1 (ja) 2005-02-17 2008-07-03 角治 東條 眼科用固形外用薬剤
US20070093520A1 (en) 2005-04-15 2007-04-26 Caras Steven D Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
US20070196518A1 (en) 2005-12-15 2007-08-23 Karol Wojewnik Composition and Method for Mitigating a Negative Effect of Alcohol Consumption
WO2007092334A1 (en) 2006-02-02 2007-08-16 Hypnion, Inc. Method of treating sleep disorders
WO2007092333A1 (en) 2006-02-03 2007-08-16 Hypnion, Inc. Use of olopatadine for treating sleep disorders
GB2435418A (en) * 2006-02-28 2007-08-29 Amalan Selvarajah Composition for preventing and alleviating alcohol hangover
WO2007103474A2 (en) 2006-03-07 2007-09-13 University Of Florida Research Foundation, Inc. Drug adherence monitoring system
US20080131532A1 (en) 2006-10-17 2008-06-05 Lorn Leitman Fast asleep
US20080113021A1 (en) * 2006-10-25 2008-05-15 Robert Shen Ibuprofen composition
JP2010513569A (ja) 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
US20100076006A1 (en) 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
WO2009029308A1 (en) 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
WO2009051628A2 (en) 2007-09-06 2009-04-23 Arezou Petrie Transdermal treatment device and method
EP2214478A1 (en) 2007-10-19 2010-08-11 Innozen, Inc. Composition for administering an active ingredient and method for making and using the same
WO2009089134A1 (en) * 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
US8440632B2 (en) * 2008-01-24 2013-05-14 Raptor Therapeutics Inc. Protopanaxadiol-type ginsenoside compositions and uses thereof
US20090258869A1 (en) 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
ES2430940T3 (es) 2008-02-28 2013-11-22 University Of Virginia Patent Foundation Gen del transportador de serotonina y tratamiento del alcoholismo
EP2288355A1 (en) * 2008-05-30 2011-03-02 Fairfield Clinical Trials LLC Method and composition for skin inflammation and discoloration
US20130029970A1 (en) 2009-07-10 2013-01-31 Ironwood Pharmaceuticals, Inc CB Receptor Agonists
EP2995303A1 (en) 2009-07-10 2016-03-16 President and Fellows of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
US20130109721A1 (en) 2009-12-08 2013-05-02 Ironwood Pharmaceuticals, Inc. FAAH Inhibitors
WO2011075688A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
US20130196960A1 (en) 2010-02-09 2013-08-01 Ironwood Pharmaceuticals, Inc. Cannabinoid Receptor Agonists
WO2012048294A2 (en) 2010-10-07 2012-04-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012088431A1 (en) 2010-12-23 2012-06-28 Ironwood Pharmaceuticals, Inc. Faah inhibitors
JP2014506894A (ja) 2011-02-28 2014-03-20 テクノロジーズ・クロロス・インク 口腔吸収用の咀嚼可能なビヒクル
RS66303B1 (sr) 2011-05-20 2025-01-31 H Lundbeck As Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
US9161957B2 (en) * 2012-08-03 2015-10-20 Life Well Lived, Llc Compositions and methods for reducing blood alcohol content
JP6276944B2 (ja) * 2013-08-29 2018-02-07 興和株式会社 フェキソフェナジンとｎｓａｉｄ含有医薬組成物
WO2015073573A1 (en) * 2013-11-14 2015-05-21 Jacobs Michael M Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome
KR102597910B1 (ko) 2015-03-26 2023-11-02 재클린 엠. 이베르센 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물
WO2019178516A1 (en) * 2018-03-16 2019-09-19 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040025331A1 (en) 2002-05-16 2004-02-12 Schmitt Klaus Gisbert Joining system head, joining system, and method of feeding and joining elements
US20050203105A1 (en) 2002-08-15 2005-09-15 Tan Oon T. Composition and method for controlling alcohol-induced facial flushing in susceptible humans
US20080021083A1 (en) 2004-03-03 2008-01-24 Daley Thomas E 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
US20110184039A1 (en) 2008-06-20 2011-07-28 Brett Antony Mooney Pharmaceutical formulation

Also Published As

Publication number Publication date
BR112017020307B1 (pt) 2023-11-07
KR20170131647A (ko) 2017-11-29
IL254641A0 (en) 2017-11-30
CA2980162A1 (en) 2016-09-29
AU2016235484A1 (en) 2017-10-12
ZA201706794B (en) 2019-02-27
US20230064685A1 (en) 2023-03-02
US20200009119A1 (en) 2020-01-09
MX2022001796A (es) 2022-03-17
MX390011B (es) 2025-03-20
US20160279112A1 (en) 2016-09-29
CN107635549A (zh) 2018-01-26
PL3273952T3 (pl) 2022-11-14
EP3973957A1 (en) 2022-03-30
BR112017020307A2 (en) 2018-06-05
JP6851365B2 (ja) 2021-03-31
JP2018509470A (ja) 2018-04-05
CA2980162C (en) 2024-06-18
EP3273952A4 (en) 2018-11-21
NZ735777A (en) 2023-03-31
WO2016154028A1 (en) 2016-09-29
AU2016235484B2 (en) 2021-02-18
US10420756B2 (en) 2019-09-24
MX2017012132A (es) 2018-07-06
US11464766B2 (en) 2022-10-11
IL254641B1 (en) 2023-09-01
ES2926494T3 (es) 2022-10-26
CN115887456A (zh) 2023-04-04
EP3273952B1 (en) 2022-06-15
EP3273952A1 (en) 2018-01-31
IL254641B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
US11464766B2 (en) Methods and compositions to inhibit symptoms associated with veisalgia
US6376550B1 (en) Pharmaceutical compositions containing tramadol for migraine
KR20200029547A (ko) 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법
US7834056B2 (en) Pharmaceutical composition for gout
US20140199417A1 (en) Antihistamines Combined with Dietary Supplements for Improved Health
EA002166B1 (ru) Фармацевтическая композиция, содержащая трамадол - лекарственное средство для лечения мигрени
CN101702884A (zh) 用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂
TW200534852A (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
US20120122919A1 (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
JP7569492B2 (ja) 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
US8058296B2 (en) Treatment and prevention of deleterious effects associated with alcohol consumption
US20180360811A1 (en) Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
ZA200207701B (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug.
US20250161270A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
CN117750956A (zh) 用于治疗抑郁状态的方法
JP2006524647A (ja) アルコール乱用治療のためのデオキシペガニンとメカミルアミンの組合せ
CN119384278A (zh) 治疗精神类疾病的方法
JP2014526488A (ja) メラトニンの新規用途
FR2916142A1 (fr) Forme pharmaceutique comprenant du (10-[(3s)-1-azabicyclo [2.2.2]oct-3-ylmethyl]-10h-phenothiazine se presentant sous une forme appropriee pour l'administration d'unde dose journaliere comprise entre 1 et 3 mg
Topcuoglu et al. Tobacco and Alcohol
US20130150375A1 (en) GEPIRONE-ER TREATMENT OF MAJOR DEPRESSION IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
KR20060094875A (ko) 코엔자임 큐텐을 유효 성분으로 함유하는 알코올성 장애의제거 및 완화제용 약학적 조성물과 그의 복용 방법
MX2007014396A (es) Composicion farmaceutica que comprende 1-(3-clorofenil)-3- alquilpiperazina para el tratamiento de trastorno alimenticio.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171026

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210318

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230709

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230915

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231031

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231031

End annual number: 3

Start annual number: 1

PG1601 Publication of registration